Home Cart Sign in  
Chemical Structure| 2095432-55-4 Chemical Structure| 2095432-55-4

Structure of SR-18292
CAS No.: 2095432-55-4

Chemical Structure| 2095432-55-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

SR-18292 functions as a PPAR gamma coactivator-1α (PGC-1α) inhibitor, augmenting PGC-1α acetylation, suppressing gluconeogenic gene expression, and reducing glucose production in hepatocytes.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of SR-18292

CAS No. :2095432-55-4
Formula : C23H30N2O2
M.W : 366.50
SMILES Code : OC(CN(C(C)(C)C)CC1=CC=C(C)C=C1)COC2=CC=CC3=C2C=CN3
MDL No. :MFCD31657330
InChI Key :BNRANURXPKRRKP-UHFFFAOYSA-N
Pubchem ID :129896798

Safety of SR-18292

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
Mouse primary hepatocytes 20μM 18 hours SR-18292 treatment increases PGC-1α acetylation and suppresses gluconeogenic gene expression PMC5398763
FaDu cells 10 µM 24 hours Inhibition of PPARGC1A-mediated mitochondrial biogenesis, leading to mitochondrial dysfunction and increased mitochondrial ROS-dependent apoptosis PMC11210931
CAL-33 cells 10 µM 24 hours Inhibition of PPARGC1A-mediated mitochondrial biogenesis, leading to mitochondrial dysfunction and increased mitochondrial ROS-dependent apoptosis PMC11210931
NK cells 20 μMol/L 48 hours To explore the effect of SR-18292 on DHA-induced mitochondrial metabolism and IFNγ production in NK cells, results showed that SR-18292 reversed the enhancement of IFNγ production, mitochondrial mass, and membrane potential by DHA. PMC11148550
LGKC1 cells 40 μM 48 hours Inhibition of PGC1α, reducing the growth of IPMN organoids PMC8709878
Human IPMN organoids 40 μM Inhibition of PGC1α, reducing organoid growth PMC8709878
Human CD34+ cells 1.0, 2.5, 5.0, 7.5 μM 11 days To investigate the effects of SR-18292 on PGC-1α and γ-globin expression in human CD34+ cells, the results showed that SR-18292 significantly increased PGC-1α and γ-globin mRNA levels and increased the proportion of F-cells. PMC11290485
mouse primary hepatocytes 1μM overnight suppressed glucagon-induced glucose secretion by ~58% PMC11555401
brown adipocytes 1μM 30 minutes suppressed norepinephrine-induced lipolysis by ~26% PMC7869975

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet-induced type 2 diabetes model Intraperitoneal injection 250 mg/kg Daily for four days SR-18292 reduces fasting blood glucose and improves glucose homeostasis PMC5398763
BklNbt:BALB/c/nu/nu mice oral cancer xenograft models subcutaneous injection 0.275 mg every 2 days for 2 weeks Co-treatment of SR-18292 with cisplatin synergistically suppresses tumor growth, increases TUNEL-positive cells, indicating synergistic induction of apoptosis PMC11210931
Mice β-YAC mice and sickle cell disease (SCD) mice Intraperitoneal injection 20 mg/kg once daily for 14 days To investigate the effects of SR-18292 on γ-globin expression in β-YAC mice and SCD mice, the results showed that SR-18292 significantly increased γ-globin and PGC-1α mRNA levels and increased the proportion of F-cells, while reducing the number of sickled red blood cells and reticulocytes, alleviating disease symptoms. PMC11290485
mice high-fat diet-induced diabetic mouse model intraperitoneal injection 200 mg/kg Once daily for 9 weeks reduced fasting blood glucose and improved insulin sensitivity PMC7869975

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.73mL

0.55mL

0.27mL

13.64mL

2.73mL

1.36mL

27.29mL

5.46mL

2.73mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories